Q-omics provides the consensus-scored NUDT14 profile across patient tissues and cancer cell-line models. NUDT14 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, NUDT14 is differentially expressed in 12, with the highest sampling consensus in COAD. Additionally, NUDT14 protein abundance shows 17,201 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight UVM, COAD, and GBM as cancer lineages where NUDT14 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NUDT14 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NUDT14 survival associations across molecular data types. NUDT14 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (2) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NUDT14 RNA expression–survival associations across cancer types. High NUDT14 expression shows unfavorable associations in UVM, LAML and SKCM, but favorable associations in LUAD, KIRC and CESC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for NUDT14 RNA expression.
This table summarizes NUDT14 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 3. The strongest signals are observed in COAD for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for NUDT14. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NUDT14 shows higher tumor expression in COAD, HNSC, THCA, LIHC, BLCA and UCEC. The COAD box plot shows higher NUDT14 RNA expression in tumor versus normal tissue (log2 FC = +1.120, t-test p < 0.001).
This table shows molecular features associated with NUDT14 in patient tissues and cancer cell lines. In patient samples, NUDT14 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, NUDT14 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and SOFT_TISSUE.
